引用本文:[点击复制]
[点击复制]
【打印本页】 【在线阅读全文】【下载PDF全文】 查看/发表评论下载PDF阅读器关闭

←前一篇|后一篇→

过刊浏览    高级检索

本文已被:浏览 156次   下载 36 本文二维码信息
码上扫一扫!
妈富隆联合曼月乐治疗子宫腺肌病的临床对比研究
李英,丁静,赵成梅
0
(达州市中西医结合医院妇产科)
摘要:
【摘要】 目的 比较口服妈富隆与妈富隆联合宫腔内置入曼月乐治疗子宫腺肌病的临床疗效与安全性。方法 入选妇科2014年7月~2015年12月收治的84例子宫腺肌病患者,随机分为妈富隆组和联合组各42例,两组分别给予口服妈富隆与妈富隆联合曼月乐宫内置入治疗,比较两组患者治疗后1、3、6个月时痛经评分、月经量评分、血清CA125、子宫大小变化及不良反应。结果 联合组患者治疗后1、3、6月痛经评分(154±049)、(097±031)和(062±023)均显著低于妈富隆组(178±054)、(120±037)和(083±029)(P<005);联合组治疗后3月、6月月经量评分(7860±1145)和(6750±1053)显著低于妈富隆组(9055±1567、8283±1409)(P<005);联合组治疗后3月、6月CA125水平[(8588±2452)U/ml、(7145±1951)U/ml]显著低于妈富隆组[(10221±2944)U/ml、(9088±2333)U/ml](P<005);两组治疗后子宫体积、不良反应发生率差异均无统计学意义(P>005)。结论 妈富隆联合曼月乐宫内置入较单纯口服妈富隆治疗子宫腺肌病能进一步缓解临床症状,降低CA125水平,且未明显增加不良反应。
关键词:  子宫腺肌病;曼月乐;妈富隆;月经量;痛经评分  子宫体积
DOI:
基金项目:达州市科技局科技与发展计划课题 (14D086)
Clinical study of Marvelon combined with and without Mirena in the treatment of adenomyosis
Li Ying,DING Jing,ZHAO Chengmei
(Department of Obstetrics and Gynecology, The Combine Traditional Chinese and Western Medicine Hospital of Dazhou)
Abstract:
【Abstract】 Objective To explore efficacy and safety of Marvelon combined with and without Mirena intrauterine placement in the treatment of adenomyosis. Methods 84 adenomyosis patients from July 2014 to December 2015 were enrolled in the study and randomly divided into Marvelon group and combined group, each group with 42 cases, which were treated with Marvelon and Marvelon combined with Mirena respectively. 1 month, 3 months and 6 months after treatment, variations on dysmenorrhea score, menstruation volume, serum CA125 level, uterine volume and adverse reactions were observed. Results The dysmenorrhea scores after 1month, 3 months and 6 months of Combined group (154±049,097±031,062±023) were all significantly lower than that of Marvelon group (178±054,120±037,083±029) (P<005). The menstruation volume scores 3 months and 6 months after treatment (7860±1145,6750±1053) were significantly lower than that of Marvelon group (9055±1567,8283±1409)(P<005). CA125 level 3 months and 6 months after treatment [(8588±2452)U/ml,(7145±1951)U/ml]were significantly lower than that of Marvelon group [(10221±2944)U/ml, (9088±2333)U/ml] (P<005). The uterine volume after treatment of the two groups showed no significant differences (P>005). The incidences of adverse reactions of the two groups during treatment had no statistically significant differences (P>005). Conclusion Marvelon combined with Mirena can further relieve clinical symptoms and reduce CA125 level, and with no increase of adverse reactions of adenomyosis.
Key words:  Adenomyosis  Mirena  Marvelon  Menstruation volume  Dysmenorrhea score  Uterine volume

用微信扫一扫

用微信扫一扫